Zobrazeno 1 - 10
of 150
pro vyhledávání: '"Francesco, Facchinetti"'
Autor:
Damien Vasseur, Ludovic Bigot, Kristi Beshiri, Juan Flórez-Arango, Francesco Facchinetti, Antoine Hollebecque, Lambros Tselikas, Mihaela Aldea, Felix Blanc-Durand, Anas Gazzah, David Planchard, Ludovic Lacroix, Noémie Pata-Merci, Catline Nobre, Alice Da Silva, Claudio Nicotra, Maud Ngo-Camus, Floriane Braye, Sergey I. Nikolaev, Stefan Michiels, Gérôme Jules-Clement, Ken André Olaussen, Fabrice André, Jean-Yves Scoazec, Fabrice Barlesi, Santiago Ponce, Jean-Charles Soria, Benjamin Besse, Yohann Loriot, Luc Friboulet
Publikováno v:
Molecular Cancer, Vol 23, Iss 1, Pp 1-16 (2024)
Abstract Background Understanding the resistance mechanisms of tumor is crucial for advancing cancer therapies. The prospective MATCH-R trial (NCT02517892), led by Gustave Roussy, aimed to characterize resistance mechanisms to cancer treatments throu
Externí odkaz:
https://doaj.org/article/e6a5668f34d34175ab097af1e5bb22e4
Autor:
Damien Vasseur, Ahmadreza Arbab, Fabiola Giudici, Christophe Marzac, Stefan Michiels, Marco Tagliamento, Arnaud Bayle, Cristina Smolenschi, Madona Sakkal, Mihaela Aldea, Hela Sassi, Filippo Gustavo Dall’Olio, Noémie Pata-Merci, Sophie Cotteret, Alice Fiévet, Nathalie Auger, Luc Friboulet, Francesco Facchinetti, Arthur Géraud, Santiago Ponce, Antoine Hollebecque, Benjamin Besse, Jean Baptiste Micol, Antoine Italiano, Ludovic Lacroix, Etienne Rouleau
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-10 (2024)
Abstract Next-generation sequencing (NGS) assays based on plasma cell-free DNA (cfDNA) are increasingly used for clinical trials inclusion. Their optimized limit of detection applied to a large number of genes leads to the identification of mutations
Externí odkaz:
https://doaj.org/article/4130073b97594d488656afc4bdbd62db
Autor:
Giorgia Guaitoli, Lodovica Zullo, Marcello Tiseo, Matthew Dankner, April AN Rose, Francesco Facchinetti
Publikováno v:
Drugs in Context, Vol 12, Pp 1-19 (2023)
BRAF mutations are reported in about 3–5% of non-small-cell lung cancer (NSCLC), almost exclusively in adenocarcinoma histology, and are classified into three different classes. The segmentation of BRAF mutations into V600 (class 1) and non-V600 (c
Externí odkaz:
https://doaj.org/article/bf8987148ca8470591581cb620ec58f8
Autor:
Giuseppe L. Banna, Marcello Tiseo, Diego L. Cortinovis, Francesco Facchinetti, Joachim G. J. V. Aerts, Cinzia Baldessari, Raffaele Giusti, Emilio Bria, Francesco Grossi, Rossana Berardi, Alessandro Morabito, Annamaria Catino, Carlo Genova, Francesca Mazzoni, Alain Gelibter, Francesca Rastelli, Marianna Macerelli, Rita Chiari, Stefania Gori, Giovanni Mansueto, Fabrizio Citarella, Luca Cantini, Erika Rijavec, Federica Bertolini, Federico Cappuzzo, Alessandro De Toma, Alex Friedlaender, Giulio Metro, Maria Vittoria Pensieri, Giampiero Porzio, Corrado Ficorella, David J. Pinato, Alessio Cortellini, Alfredo Addeo
Publikováno v:
Thoracic Cancer, Vol 13, Iss 3, Pp 483-488 (2022)
Abstract Background Patients with programmed cell death‐ligand 1 (PD‐L1) ≥50% metastatic non‐small cell lung cancer (mNSCLC) and ECOG performance status (PS) of 2 treated with first‐line immunotherapy have heterogeneous clinical assessment
Externí odkaz:
https://doaj.org/article/c6c73bc779d045abbf30461995e450e6
Publikováno v:
Case Reports in Ophthalmology, Vol 12, Iss 1, Pp 288-292 (2021)
We describe the case of Gefitinib-related bilateral corneal perforation. An 86-year-old female patient had bilateral painless and progressive vision loss due to neurotrophic corneal ulcer, following a 2-month treatment with Gefitinib, a selective epi
Externí odkaz:
https://doaj.org/article/c76bf22856674e3d8725f0441c8a2d58
Autor:
James Artingstall, Alex Friedlaender, Alfredo Addeo, Judith Cave, Massimo Di Maio, Samuel Chan, Alessio Cortellini, Marcello Tiseo, Biagio Ricciuti, Francesco Facchinetti, Benjamin Besse, Joao V Alessi, Mark M Awad, David J Pinato, Giuseppe L Banna, Giuseppe Lamberti, Margarita Majem, Frank Aboubakar Nana, Charles Comins, Thomas Newsom-Davis, Victor R Vaz, Laura Mezquita, Davide Soldato, Filippo G Dall’Olio, Sethupathi Muthuramalingam, Aida Piedra, Elisa Andrini, Teresa Gorría, Delphine Hoton, Lacroix Valerie, Andrea Caglio, Hayley McKenzie, Joanne S Evans, Antonio D'Alessio, Claudia A M Fulgenzi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is
Externí odkaz:
https://doaj.org/article/0d868f118ef644a68eebc13a655c68ba
Autor:
Roberta Minari, PhD, Samuel Valentini, MSc, Denise Madeddu, PhD, Andrea Cavazzoni, PhD, Silvia La Monica, PhD, Costanza Anna Maria Lagrasta, MSc, Roberto Bertorelli, MSc, Veronica De Sanctis, PhD, Paola Fassan, MSc, Cinzia Azzoni, PhD, Lorena Bottarelli, PhD, Caterina Frati, PhD, Letizia Gnetti, MD, Francesco Facchinetti, MD, Pier Giorgio Petronini, PhD, Roberta Alfieri, PhD, Alessandro Romanel, PhD, Marcello Tiseo, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 2, Pp 100278- (2022)
Introduction: ALK tyrosine kinase inhibitors (TKIs) are the standard treatment for advanced ALK-positive NSCLC. Nevertheless, drug resistance inevitably occurs. Here, we report a case of a patient with metastatic ALK-positive lung adenocarcinoma with
Externí odkaz:
https://doaj.org/article/e7a0f0aaa4584907a17791252608959c
Publikováno v:
European Respiratory Review, Vol 30, Iss 162 (2021)
The advent of immune checkpoint inhibitors (ICIs) has rapidly transformed the treatment paradigm for multiple cancer types, including thoracic malignancies. In advanced non-small cell lung cancer (NSCLC), ICIs have shifted treatment paradigm and impr
Externí odkaz:
https://doaj.org/article/26b6c0f11ece4552aa371f3572291992
Autor:
Filippo G. Dall’Olio, Francesca Abbati, Francesco Facchinetti, Maria Massucci, Barbara Melotti, Anna Squadrilli, Sebastiano Buti, Francesca Formica, Marcello Tiseo, Andrea Ardizzoni
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Aims: To assess prognostic value of pre-therapy carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) blood levels in non-small cell lung cancer (NSCLC) patients treated with immune-checkpoint inhibitors (ICIs) and their early chan
Externí odkaz:
https://doaj.org/article/86efd4aa996242a1bf8707aef0f48a30
Autor:
Diego Enrico, MD, Ludovic Lacroix, PharmD, PhD, Jeanne Chen, MD, Etienne Rouleau, PharmD, PhD, Jean-Yves Scoazec, MD, PhD, Yohann Loriot, MD, PhD, Lambros Tselikas, MD, Cécile Jovelet, PharmD, PhD, David Planchard, MD, PhD, Anas Gazzah, MD, Laura Mezquita, MD, PhD, Maud Ngo-Camus, MSc, Stefan Michiels, PhD, Christophe Massard, MD, PhD, Gonzalo Recondo, MD, PhD, Francesco Facchinetti, MD, Jordi Remon, MD, Jean-Charles Soria, MD, PhD, Fabrice André, MD, PhD, Gilles Vassal, MD, PhD, Luc Friboulet, PhD, Benjamin Besse, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100023- (2020)
Introduction: Despite initial benefit, virtually all patients suffering from EGFR-mutant NSCLC experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by multiple mechanisms. Recent reports have identified oncogenic kinase fusions
Externí odkaz:
https://doaj.org/article/1bd1d67570ef49619261081550260f89